Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 52.1%

Neg 0% Neu 52.1% Pos 0%

Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.